DOCSLIB.ORG

Genes in Eyecare Geneseyedoc 3 W.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease. This simplistic assumption would sometimes be incorrect. The most common cause of genetic disorders is multifactorial inheritance which includes genes and environmental factors. Single gene disorders appear in about 1/100 newborn and chromosomall abnormalities in about 1/150. Gene symbols are written in BOLD ITALICS. The indicated gene may be mutated, deleted, duplicated, or translocated to a different location. Nearly two thousand genes are mentioned. Ongoing research provides new information so that specific details need frequent updating. The reader is reminded that this is of necessity a work in progress: we will update information as it becomes available. Comments and suggestions from readers are welcomed. A. Name Gene Comments Aarskog-Scott, FGDY, FGD1, AAS Females are only partly affected, males have lax joints, abnormal facial-digital-genital at Xp11.21,or at Xq13. cervical vertebrae, short stature, shawl scrotum, clinodactyly, and syndrome. hypertelorism. (XR, XD). MIM 100050 Aase-Smith syndrome-I. PHA3 at 17p11-q21 Hydrocephalus, Dandy-Walker malformation, congenital joint (AD). MIM 147800 contractures, congenital neuroblastoma, ventricular septal defects, cleft palate, ptosis, and death in infancy. See distal arthrogryposis-IIB (MIM 601680), Marden-Walker (MIM 108120, 248700), and Gordon syndromes (MIM 114300). Aase-Smith syndrome-II. Gene Congenital hypoplastic anemia, triphalangeal thumbs, and distal (AD). MIM 205600 arthrogryposis. Compare with Diamond-Blackfan anemia.(AR, AD), DBA at 19q13.2. (MIM 205900 abetalipoproteinemia APOB at 2p24-p22 Bassen-Kornzweig syndrome, unable to synthesize the (AR). MIM 200100, 107730 for a microsomal apolipoprotein B peptide of low density lipoprotein, fail to absorb triglyceride-transfer and transport lipoproteins, have hypolipoproteinemia, protein. hypocholesterolemia, coronary artery disease, ataxia, muscle weakness, kyphosis, slurred speech. Signs develop after age 10. May have ptosis, nystagmus, ophthalmoplegia, macular degeneration, and retinopathy. Treat with vitamins A and E. See also Abelson leukemia (AD) ABL at 9q34.1 (MIM 189980) abetalipoproteinemia. (AR) MTP at 4q22-q24 A defect in a microsomal triglyceride transfer protein causes another abetalipoproteinemia. ABO blood type (AD) ABO at 9q34 More risk of peptic ulcer and thromboembolic disease. See adenylate kinase deficiency. (MIM 103000). acanthocytosis . AEI, EPB3, SLC4A1 Have spherocytosis and anemia. (S, AR, AD) at 17q21-q22. See MIM 100500, 200150. acanthosis nigricans (AD) INSR at 19p13.3. Insulin receptor gene. See diabetes. acatalasemia. (AD) CAT at 11p13. Takahara disease with ulcers of the gums. Achard syndrome. Gene A connective tissue disorder, an atypical Marfan syndrome, (AD). MIM 100700 arachnodactyly, with micrognathia and ligament and joint laxity in hands and feet. May be similar to Marfan syndome. (MIM 154700). See also Achard-Levi syndrome which can be caused by a midbrain stroke. Have dysostosis and ligament laxity. See also Achard-Thiers syndrome, diabetes in bearded women. achondrodysgenesis DTD, DTDST Diastrophic dysplasia. Subtypes include: type 1 ACG1A (MIM (AR, rarely AD) at 5q32-q33 200600), type 2 ACG2 (MIM 200610), type 3 (MIM 200710), and MIM 222600 . type 4 (MIM 200720). See MIM 200700 for Grebe (AR) dysplasia CDMP1 at 20q11.2 (MIM 601146), CDMP2, (MIM 601147). achondroplasia ACH, FGFR3 at 4p16.3 Robinow-Silverman-Smith syndrome, incidence 1/20,000, with (S, AD, AR). MIM 134934 is a negative regulator dwarfism, skeletal anomalies, deafness, strabismus, hyperopia, of bone growth. and optic atrophy. Achondroplasia is the commonest skeletal dysplasia and produces the most frequent form of short-limb dwarfism. achondrodysgenesis- COL2A1 Short-limb dwarfism. hypochondro-dysgenesis-II. at 12q13.11-q13.2 (AD) F syndrome Gene may be Acropectorovertebral syndrome, skeletal dysplasia, and often (AD). MIM 102510 LMBR1 at 7q36 syndactyly. ACHOO syndrome Gene May affect 25% of the population. (AD). MIM 100820 A photic stimulus induces a single or a multiple sneeze reflex. achromatopsia. (AR) See color vision. Ackerman glaucoma. (AR) Gene Have juvenile glaucoma and dental defects. acrocephalopoly-syndactyly. FGFR2 at 10q25.3-q26 See Pfeiffer, formerly Noack syndrome, also called ACSV. ACPS. type I. (AR, AD) Craniosynostosis, broad thumb and great toe, and polysyndactyly. ACPS. type II. FGFR2 at 10q25.3-q26 Carpenter syndrome with mental retardation, craniosynostosis, (AR). MIM 201000 preaxial polydactyly, brachydactyly, syndactyly, and corneal opacities. Is a severe form of Apert syndrome. (MIM 101200). ACPS. type III Genes. Sakati-Nyhan-Tisdale syndrome is rare. (AD). MIM 101120 Craniosynostosis, acrocephaly, leg hypoplasia, preaxial polydactyly, and hypertelorism. ACPS. type IV Genes. The Goodman and Summitt syndromes are both variants of zaeus . MIM 201020, 272350 Carpenter syndrome, with obesity, acrocephaly, syndactyly, and polydactyly. acrocephalosyndactyly, FGFR2 at 10q25.3-q26 Apert syndrome is also called ACPS2, incidence 1/130,000, signs ACS. type I. are. oxycephaly (tower skull), parrot-beaked nose, (AD, AR). MIM 101200 hydronephrosis, syndactyly, hypertelorism, exophthalmos, and external strabismus. Mutations in FGFR2 are involved in several syndromes: Apert (MIM 101200), Carpenter (MIM 201000), Crouzon (MIM 123500), Jackson-Weiss (MIM 123150), and others. ACS. type II TWIST at 7p22-p21 Robinow-Sorauf syndrome patients may have polydactyly of the (AD). MIM 180750 great toes but otherwise resemble Saethre-Chotzen syndrome. ACS. type III SCS, TWIST Saethre-Chotzen syndrome, signs are craniosynostosis, pointed (AD). MIM 101400 at 7p22-p21 nose, cleft palate, heart defect, hypertelorism, and strabismus. A few have learning disability or are mentally retarded. ACS. type IV ACS IV Also called Robinow -Sorauf syndrome. Clinodactyly, (AD). MIM 180750 camptodactyly, ulnar deviation, hypertelorism, and strabismus. Resembles Saethre-Chotzen syndrome (AD) (MIM 101400). ACS. type V FGFR2 at 10q25.3-q26, See Pfeiffer, Crouzon, Noack, and Apert syndromes. (AD) MIM 101600 FGFR1 at 8p11.2-p11.1 Can also cause cancer. acoustic neuroma. (AD, S) NF2 at 22q12.2 Compare with NF1 at 17q11.2. acrodermatitis enteropathica Gene may be Zinc deficiency manifests in infancy, acrodermatitis, diarrhea, and (AR). MIM 201100 SLC39A4 at 8q24. failure to thrive. acrofacial dysostosis (AD) AFDN at 9q32 See Nager syndrome. (MIM 154400) acromegaloid changes, ACL Rosenthal-Kloepfer syndrome onset by age 1 year. cutis verticis gyrata, Tall with large hands and feet, longitudinal folds in scalp skin, and corneal leukoma pituitary tumors, keratitis and bilateral corneal leukomas. (AD). MIM 102100 acrorenoocular or Gene Thumb hypoplasia, polydactyly, horseshoe kidney, mental acral-renal-ocular syndrome retardation, Duane anomaly (MIM 126800), ptosis, and optic (AD, AR). MIM 102490 nerve colobomas. (MIM 126800). acromicric dysplasia. Gene Severe growth retardation, short hands and feet, carpal tunnel (AD). MIM 102370 syndrome, hoarse voice, and mild facial anomalies. See Moore-Federman syndrome (AD), (MIM 127200). acute retinal necrosis ARN or BARN Bilateral retinal necrosis is mostly caused by a herpes infection. syndrome See Leigh syndrome. (MIM 256000), and can occur with a varicella-zoster virus infection. acyl CoA dehydrogenase ACADS, SCAD Short chain type, very rare.. Deficiency of mitochondrial short deficiency. type 1. on chromosome 12 chain acyl, CoA, butyryl CoA.. Can manifest in infancy or later (AR). MIM 201470 in life. acyl CoA dehydrogenase ACADH, ACADM at 1p31. Medium chain type, carnitine deficiency, CACT at 3p21.31. deficiency. type 2. A deficiency of acyl CoA occurs in 1/10,000 births. (AR). MIM 201450 With this deficiency the child can die at about age 2 years. Some have Reye syndrome, (AR) SCD at 5q31.1(MIM 212140) adrenal unresponsiveness.. acyl CoA dehydrogenase ACADL, LCAD Long chain type. LCAD deficiency has its onset before age 6 deficiency.
Recommended publications
  • Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System

    Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 23 April 2018 doi:10.20944/preprints201804.0275.v1 1 Review 2 Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System 3 Martin L. Nelwan 4 Department of Animal Science – Other 5 Nelwan Institution for Human Resource Development 6 Jl. A. Yani No. 24 7 Palu, Sulawesi Tengah, Indonesia 8 Email: [email protected] 9 Abstract: Antisocial behavior is a behavior disorder inherited according to the inheritance of X-linked 10 chromosome. Mutations in the MAOA gene can cause different behaviors in humans. These can comprise 11 violent behavior or antisocial behavior. Low MAOA (MAOA-L) allele activity can cause antisocial 12 behavior in both healthy and unhealthy people. Antisocial from healthy males can originate from 13 maltreatment during childhood. There are no drugs for the treatment of antisocial behavior permanently 14 at this time. MAOA inhibitor can reverse antisocial behavior in animal models. To cure antisocial 15 behavior in the future, the CRISPR/Cas9 system in combination with iPSCs or ssODN methods for 16 instance can be used. This system has succeeded to correct erroneous segments in the F8 gene and F9 17 gene. Both genes occupy the X chromosome. The MAOA gene also occupies the X chromosome. It seems 18 that CRISPR/Cas9 system may be a beneficial tool to edit erroneous segments in the MAOA gene to treat 19 antisocial behavior. 20 Keywords: advanced therapy, aggressive, antisocial, behavior, MAOA. 21 22 1. Introduction 23 Antisocial behavior is a hereditary disorder inherited through an X-linked recessive inheritance 24 pattern.
  • Color Blindness LEVELED BOOK • W a Reading A–Z Level W Leveled Book Word Count: 1,349 Color Blindness Connections Writing Choose Two Forms of Color Blindness

    Color Blindness LEVELED BOOK • W a Reading A–Z Level W Leveled Book Word Count: 1,349 Color Blindness Connections Writing Choose Two Forms of Color Blindness

    Color Blindness LEVELED BOOK • W A Reading A–Z Level W Leveled Book Word Count: 1,349 Color Blindness Connections Writing Choose two forms of color blindness. Write a report that compares the two conditions and their effects on a person’s life. Math Research the statistics about the number of people with the various forms of color blindness in your country. Organize your results in a pie chart. • W Q •T Written by Cheryl Reifsnyder Visit www.readinga-z.com for thousands of books and materials. www.readinga-z.com Words to Know Color ancestry molecules complementary photopigments cone cells prism Blindness defects retina genetic disorder rod cells hereditary wavelengths Photo Credits: Front cover, Back cover: © pretoperola/123RF; title page (Both): © shironosov/ iStock/Thinkstock; page 3: © Véronique Burger/Science Source; page 4 (Both): © Michael Shake/Dreamstime.com; page 5: © Designua/Dreamstime.com; page 6 (top): © Gunilla Elam/Science Source; page 6 (Bottom): © Steve Gschmeissner/Science Source; page 7 (Both): © Ted Kinsman/ Science Source; page 8 (left, Both): © anatchant/iStock/Thinkstock; page 8 (center, Both): © Nadezhda Bolotina/Hemera/Thinkstock; page 8 (right, Both): © iremphotography/iStock/Thinkstock; page 9 (all): © Popartic/iStock Editorial/Thinkstock; page 10: © RVN/Alamy Stock Photo; page 12: © Alexander Kaludov/123RF; page 13: © EnChroma; page 14: © Neitz LaBoratory; page 15: © Phanie/Alamy Stock Photo Written by Cheryl Reifsnyder www.readinga-z.com Focus Question Color Blindness Level W Leveled Book Correlation © Learning A–Z LEVEL W Written By Cheryl Reifsnyder What causes color blindness, and how Fountas & Pinnell S can it affect a person’s life? All rights reserved.

  • RETINAL DISORDERS Eye63 (1)

    RETINAL DISORDERS Eye63 (1) Retinal Disorders Last updated: May 9, 2019 CENTRAL RETINAL ARTERY OCCLUSION (CRAO) ............................................................................... 1 Pathophysiology & Ophthalmoscopy ............................................................................................... 1 Etiology ............................................................................................................................................ 2 Clinical Features ............................................................................................................................... 2 Diagnosis .......................................................................................................................................... 2 Treatment ......................................................................................................................................... 2 BRANCH RETINAL ARTERY OCCLUSION ................................................................................................ 3 CENTRAL RETINAL VEIN OCCLUSION (CRVO) ..................................................................................... 3 Pathophysiology & Etiology ............................................................................................................ 3 Clinical Features ............................................................................................................................... 3 Diagnosis .........................................................................................................................................
  • Visual Recognition of Autoimmune Connective Tissue Diseases

    Visual Recognition of Autoimmune Connective Tissue Diseases

    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
  • Crouzon Syndrome Genetic and Intervention Review

    Crouzon Syndrome Genetic and Intervention Review

    Journal of Oral Biology and Craniofacial Research 9 (2019) 37–39 Contents lists available at ScienceDirect Journal of Oral Biology and Craniofacial Research journal homepage: www.elsevier.com/locate/jobcr Crouzon syndrome: Genetic and intervention review ∗ T N.M. Al-Namnama, , F. Haririb, M.K. Thongc, Z.A. Rahmanb a Department of Oral Biology, Faculty of Dentistry, University of MAHSA, 42610, Jenjarum, Selangor, Malaysia b Department of Oro-Maxillofacial Clinical Science, Faculty of Dentistry, University of Malaya, 50603, Kuala Lumpur, Malaysia c Department of Paediatrics, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia ARTICLE INFO ABSTRACT Keywords: Crouzon syndrome exhibits considerable phenotypic heterogeneity, in the aetiology of which genetics play an Crouzon syndrome important role. FGFR2 mediates extracellular signals into cells and the mutations in the FGFR2 gene cause this Molecular pathology syndrome occurrence. Activated FGFs/FGFR2 signaling disrupts the balance of differentiation, cell proliferation, Genetic phenotype and apoptosis via its downstream signal pathways. However, very little is known about the cellular and mole- cular factors leading to severity of this phenotype. Revealing the molecular pathology of craniosynostosis will be a great value for genetic counselling, diagnosis, prognosis and early intervention programs. This mini-review summarizes the fundamental and recent scientific literature on genetic disorder of Crouzon syndrome and presents a graduated strategy for the genetic approach, diagnosis and the management of this complex cra- niofacial defect. 1. Introduction known. CS commonly starts at the first three years of life.4 Craniosy- nostosis can be suspected during antenatal stage via ultrasound scan Craniosynostosis is a birth defect characterized by premature fusion otherwise is often detected at birth from its classic crouzonoid features of one or more of the calvarial sutures before the completion of brain of the newborn.
  • Peripheral Neuropathy in Complex Inherited Diseases: an Approach To

    Peripheral Neuropathy in Complex Inherited Diseases: an Approach To

    PERIPHERAL NEUROPATHY IN COMPLEX INHERITED DISEASES: AN APPROACH TO DIAGNOSIS Rossor AM1*, Carr AS1*, Devine H1, Chandrashekar H2, Pelayo-Negro AL1, Pareyson D3, Shy ME4, Scherer SS5, Reilly MM1. 1. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 2. Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 3. Unit of Neurological Rare Diseases of Adulthood, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy. 4. Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA 5. Department of Neurology, University of Pennsylvania, Philadelphia, PA 19014, USA. * These authors contributed equally to this work Corresponding author: Mary M Reilly Address: MRC Centre for Neuromuscular Diseases, 8-11 Queen Square, London, WC1N 3BG, UK. Email: [email protected] Telephone: 0044 (0) 203 456 7890 Word count: 4825 ABSTRACT Peripheral neuropathy is a common finding in patients with complex inherited neurological diseases and may be subclinical or a major component of the phenotype. This review aims to provide a clinical approach to the diagnosis of this complex group of patients by addressing key questions including the predominant neurological syndrome associated with the neuropathy e.g. spasticity, the type of neuropathy, and the other neurological and non- neurological features of the syndrome. Priority is given to the diagnosis of treatable conditions. Using this approach, we associated neuropathy with one of three major syndromic categories - 1) ataxia, 2) spasticity, and 3) global neurodevelopmental impairment. Syndromes that do not fall easily into one of these three categories can be grouped according to the predominant system involved in addition to the neuropathy e.g.
  • 2018 Etiologies by Frequencies

    2018 Etiologies by Frequencies

    2018 Etiologies in Order of Frequency by Category Hereditary Syndromes and Disorders Count CHARGE Syndrome 958 Down syndrome (Trisomy 21 syndrome) 308 Usher I syndrome 252 Stickler syndrome 130 Dandy Walker syndrome 119 Cornelia de Lange 102 Goldenhar syndrome 98 Usher II syndrome 83 Wolf-Hirschhorn syndrome (Trisomy 4p) 68 Trisomy 13 (Trisomy 13-15, Patau syndrome) 60 Pierre-Robin syndrome 57 Moebius syndrome 55 Trisomy 18 (Edwards syndrome) 52 Norrie disease 38 Leber congenital amaurosis 35 Chromosome 18, Ring 18 31 Aicardi syndrome 29 Alstrom syndrome 27 Pfieffer syndrome 27 Treacher Collins syndrome 27 Waardenburg syndrome 27 Marshall syndrome 25 Refsum syndrome 21 Cri du chat syndrome (Chromosome 5p- synd) 16 Bardet-Biedl syndrome (Laurence Moon-Biedl) 15 Hurler syndrome (MPS I-H) 15 Crouzon syndrome (Craniofacial Dysotosis) 13 NF1 - Neurofibromatosis (von Recklinghausen dis) 13 Kniest Dysplasia 12 Turner syndrome 11 Usher III syndrome 10 Cockayne syndrome 9 Apert syndrome/Acrocephalosyndactyly, Type 1 8 Leigh Disease 8 Alport syndrome 6 Monosomy 10p 6 NF2 - Bilateral Acoustic Neurofibromatosis 6 Batten disease 5 Kearns-Sayre syndrome 5 Klippel-Feil sequence 5 Hereditary Syndromes and Disorders Count Prader-Willi 5 Sturge-Weber syndrome 5 Marfan syndrome 3 Hand-Schuller-Christian (Histiocytosis X) 2 Hunter Syndrome (MPS II) 2 Maroteaux-Lamy syndrome (MPS VI) 2 Morquio syndrome (MPS IV-B) 2 Optico-Cochleo-Dentate Degeneration 2 Smith-Lemli-Opitz (SLO) syndrome 2 Wildervanck syndrome 2 Herpes-Zoster (or Hunt) 1 Vogt-Koyanagi-Harada
  • RD-Action Matchmaker – Summary of Disease Expertise Recorded Under

    RD-Action Matchmaker – Summary of Disease Expertise Recorded Under

    Summary of disease expertise recorded via RD-ACTION Matchmaker under each Thematic Grouping and EURORDIS Members’ Thematic Grouping Thematic Reported expertise of those completing the EURORDIS Member perspectives on Grouping matchmaker under each heading Grouping RD Thematically Rare Bone Achondroplasia/Hypochondroplasia Achondroplasia Amelia skeletal dysplasia’s including Achondroplasia/Growth hormone cleidocranial dysostosis, arthrogryposis deficiency/MPS/Turner Brachydactyly chondrodysplasia punctate Fibrous dysplasia of bone Collagenopathy and oncologic disease such as Fibrodysplasia ossificans progressive Li-Fraumeni syndrome Osteogenesis imperfecta Congenital hand and fore-foot conditions Sterno Costo Clavicular Hyperostosis Disorders of Sex Development Duchenne Muscular Dystrophy Ehlers –Danlos syndrome Fibrodysplasia Ossificans Progressiva Growth disorders Hypoparathyroidism Hypophosphatemic rickets & Nutritional Rickets Hypophosphatasia Jeune’s syndrome Limb reduction defects Madelung disease Metabolic Osteoporosis Multiple Hereditary Exostoses Osteogenesis imperfecta Osteoporosis Paediatric Osteoporosis Paget’s disease Phocomelia Pseudohypoparathyroidism Radial dysplasia Skeletal dysplasia Thanatophoric dwarfism Ulna dysplasia Rare Cancer and Adrenocortical tumours Acute monoblastic leukaemia Tumours Carcinoid tumours Brain tumour Craniopharyngioma Colon cancer, familial nonpolyposis Embryonal tumours of CNS Craniopharyngioma Ependymoma Desmoid disease Epithelial thymic tumours in
  • Appendix A: Organisation of a Craniofacial Unit

    Appendix A: Organisation of a Craniofacial Unit

    Appendix A: Organisation of a Craniofacial Unit The requirements of patients with craniofacial abnormalities are very complex and demand a multidisciplinary approach. Many body systems are affected, and every detail of patient management has to be given due attention. Care begins at birth and continues until the patient and his family have been relieved of the burden of the anomaly. A team is needed, capable of delivering expert patient care, and representative of all the relevant disciplines. Data, in the form of histories, physical examinations, and special investigations, are needed in planning treatment, and such data should be used to the maximum scientific effect, to improve present methods of management, still far from satisfactory, and to expand knowledge of the biology of cranial growth and its disorders. Craniofacial Units Sporadic craniofacial procedures performed by a surgeon on an irregular basis invite disaster. Tessier (1971a) estimated that each craniofacial centre should serve a population of 10 to 20 million people, provided that the team performed only craniofacial surgery and treated at least 50 new cases annually. As a consequence of Tessier's example and teaching there are now centres of acknowledged excellence in Paris and Nancy, attracting patients not only from France but also from North Africa and elsewhere. In North America there are now important craniofacial centres in Philadelphia, New York, Boston, Toronto, and Mexico City. Munro (1975) proposed that North America should be divided into seven regions, six for the United States and one for Canada, each serving populations of 20 to 40 million people. He believed that such centres would allow a concentration of multidisciplinary skills and accumulation of experience in the treatment of craniofacial anomalies.
  • Dominant Optic Atrophy

    Dominant Optic Atrophy

    Lenaers et al. Orphanet Journal of Rare Diseases 2012, 7:46 http://www.ojrd.com/content/7/1/46 REVIEW Open Access Dominant optic atrophy Guy Lenaers1*, Christian Hamel1,2, Cécile Delettre1, Patrizia Amati-Bonneau3,4,5, Vincent Procaccio3,4,5, Dominique Bonneau3,4,5, Pascal Reynier3,4,5 and Dan Milea3,4,5,6 Abstract Definition of the disease: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which transfer the visual information from the photoreceptors to the lateral geniculus in the brain. Epidemiology: The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000 in the rest of the world. Clinical description: DOA patients usually suffer of moderate visual loss, associated with central or paracentral visual field deficits and color vision defects. The severity of the disease is highly variable, the visual acuity ranging from normal to legal blindness. The ophthalmic examination discloses on fundoscopy isolated optic disc pallor or atrophy, related to the RGC death. About 20% of DOA patients harbour extraocular multi-systemic features, including neurosensory hearing loss, or less commonly chronic progressive external ophthalmoplegia, myopathy, peripheral neuropathy, multiple sclerosis-like illness, spastic paraplegia or cataracts. Aetiology: Two genes (OPA1, OPA3) encoding inner mitochondrial membrane proteins and three loci (OPA4, OPA5, OPA8) are currently known for DOA. Additional loci and genes (OPA2, OPA6 and OPA7) are responsible for X-linked or recessive optic atrophy.
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
  • Whole Exome Sequencing Gene Package Intellectual Disability, Version 9.1, 31-1-2020

    Whole Exome Sequencing Gene Package Intellectual Disability, Version 9.1, 31-1-2020

    Whole Exome Sequencing Gene package Intellectual disability, version 9.1, 31-1-2020 Technical information DNA was enriched using Agilent SureSelect DNA + SureSelect OneSeq 300kb CNV Backbone + Human All Exon V7 capture and paired-end sequenced on the Illumina platform (outsourced). The aim is to obtain 10 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate and non-unique reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA-MEM algorithm (reference: http://bio-bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A2ML1 {Otitis media, susceptibility to}, 166760 610627 66 100 100 96 AARS1 Charcot-Marie-Tooth disease, axonal, type 2N, 613287 601065 63 100 97 90 Epileptic encephalopathy, early infantile, 29, 616339 AASS Hyperlysinemia,